Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, idarubicin hydrochloride (Zavedos®) cannot be endorsed for use within NHS Wales for first-line treatment of acute myeloid leukaemia, in combination with cytarabine, for remission induction in children. |
||
|
||
Medicine details |
||
| Medicine name | idarubicin hydrochloride (Zavedos®) | |
| Formulation | 5 mg and 10 mg powder for solution for injection | |
| Reference number | 2607 | |
| Indication | First-line treatment of acute myeloid leukaemia, in combination with cytarabine, for remission induction in children |
|
| Company | Pfizer Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 15/05/2015 | |